UCB’s robust global R&D response during COVID-19 focused on our patients, employees, and our communities. Read more on our overall approach from UCB's Chief Medical Officer, Iris Loew-Friedrich.  

Each year, UCB has the honor of awarding our UCB Family Epilepsy Scholarship to deserving individuals living with epilepsy, their family members, and caregivers to help them fulfill their dreams. We realize that to truly make an impact on patients’ lives, we must go beyond developing and delivering medicines, and we are committed to helping patients and their families receive the financial support they need to live their best lives possible.

This August, the theme for Psoriasis Action Month is ‘All of Us.’ UCB is joining the National Psoriasis Foundation to shine light on the condition’s impact on diverse populations, and celebrate the diversity and inclusivity of the psoriasis community. Read more from Rhonda Peebles, Head of U.S. Dermatology, as she shares her thoughts on racial inequities in dermatology and the steps UCB is taking to move the equity needle forward. 

As part of Psoriasis Action Month, Camille Lee, Head of U.S. Immunology at UCB, shares how UCB is helping find and bridge gaps in psoriatic disease care. 

Tomorrow is National Intern Day 2021! We are pleased to continue our mission of investing in the next generation of the workforce by welcoming 32 student interns to our second virtual internship program.

As our health care system shifts from volume- to value-based reimbursement, industry participation in value-based contracts (VBCs) is helping drive this transformation. Read more from Head of Rare Disease Access Strategy, Kelly Guntrum, on how UCB is transforming access through value-based contracts.

With more than 90 years of innovation, at UCB, we come together every day to work, laser-focused, on a simple question: How will this create value for people living with severe diseases? Learn more about who we are at UCB.

This month in honor of Myasthenia Gravis (MG) Awareness Month, we have an opportunity to elevate the voices and needs of people with MG who remind us each day that our collective efforts can directly impact the everyday lives of MG patients – especially during times when immunocompromised individuals can face even more challenges than usual.

Today, UCB issued the following statement from Jeffrey Stark, M.D., Head of U.S. Medical Immunology, on the recent update by the ICD-10 Coordination and Maintenance Committee to endorse the creation of a new sub-category (M45.A) for non-radiographic axial spondyloarthritis (nr-axSpA).